InflaRx N.V.

Informe acción NasdaqGS:IFRX

Capitalización de mercado: US$384.4m

InflaRx Dirección

Dirección controles de criterios 2/4

El CEO de InflaRx es Niels Riedemann, nombrado en Jan 2007, tiene una permanencia de 19.33 años. posee directamente un 0.73% de las acciones de la empresa, con un valor de $2.79M. La antigüedad media del equipo directivo y de la junta directiva es de 3.8 años y 7 años, respectivamente.

Información clave

Niels Riedemann

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEOn/a
Permanencia del CEO19.3yrs
Participación del CEO0.7%
Permanencia media de la dirección3.8yrs
Promedio de permanencia en la Junta Directiva7yrs

Actualizaciones recientes de la dirección

Recent updates

Artículo de análisis • Feb 06

Here's Why We're A Bit Worried About InflaRx's (NASDAQ:IFRX) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Nov 20

InflaRx: Gohibic Remains Niche, INF904 Underwhelms, Cash Burn Accelerates (Rating Downgrade)

Summary InflaRx faces worsening prospects as Gohibic remains niche, unprofitable, and unlikely to drive meaningful revenue growth. Attempts to expand vilobelimab into new indications failed, prompting a strategic pivot to the early-stage asset INF904. Early INF904 data in HS and CSU are underwhelming, with class safety concerns and past failures weighing on IFRX's outlook. With dwindling cash reserves and a high burn rate, IFRX is rated a clear 'Sell' due to excessive risks and uncertain turnaround. Read the full article on Seeking Alpha
Artículo de análisis • Jul 10

Is InflaRx (NASDAQ:IFRX) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Artículo de análisis • Jun 25

InflaRx (NASDAQ:IFRX) Will Have To Spend Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Artículo de análisis • Dec 23

We're Keeping An Eye On InflaRx's (NASDAQ:IFRX) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Artículo de análisis • Aug 17

InflaRx (NASDAQ:IFRX) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Artículo de análisis • Mar 28

We're A Little Worried About InflaRx's (NASDAQ:IFRX) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Artículo de análisis • Nov 30

Can InflaRx (NASDAQ:IFRX) Afford To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Sep 29

InflaRx seeks FDA emergency use nod for its treatment for critically ill COVID-19 patients

German clinical-stage biopharma InflaRx (NASDAQ:IFRX) on Thursday said it had submitted an emergency use approval request to the U.S. FDA for its monoclonal antibody vilobelimab to treat critically ill COVID-19 patients. The company also said it was granted a fast track designation from the U.S. drug regulator for vilobelimab. IFRX stock +5.6% to $2.63 in early trading. The submission for the emergency use nod and the fast track clearance was based on the results of phase 3 studies conducted in invasively mechanically ventilated, critically ill COVID patients, IFRX said in a statement. The FDA's Fast Track approval is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need. The submission from InflaRx (IFRX) comes at a time when COVID cases in the U.S. are expected to rise in the fall and winter season.
Seeking Alpha • Aug 05

InflaRx reports Q2 results

InflaRx press release (NASDAQ:IFRX): Q2 GAAP EPS of €0.01. On June 30, 2022, the Company’s total funds available were approximately €91.8 million, composed of cash and cash equivalents of €15.4 million and marketable securities of €76.4 million. These funds are expected to finance operations until year-end 2024.
Seeking Alpha • Jul 26

InflaRx stock rises 13% on plans to file EUA for COVID drug in US for critically ill patients

InflaRx (NASDAQ:IFRX) stock rose ~13% on July 26 after its CEO Niels Riedemann said the company plans to submit a request for an emergency use authorization (EUA) of its COVID-19 drug vilobelimab in the U.S. by the end of Q3. The Germany company said it had encouraging interactions with the U.S. Food and Drug Administration (FDA) at a recent Type B meeting which was held to discuss a potential EUA filing and the development of monoclonal antibody vilobelimab for critically ill invasively mechanically ventilated patients with COVID-19. InflaRx noted that it discussed in detail a completed phase 3 part of the PANAMO study in invasively mechanically ventilated, critically ill patients with COVID-19. In March, the company reported data from the phase 3 trial in which vilobelimab did not show statistical significance in reducing risk of death in mechanically ventilated patients with COVID-19. "Our constructive interactions with the FDA and the helpful guidance they provided have encouraged us to move forward with applying for EUA for vilobelimab in critically ill COVID-19 patients," said InflaRx Founder and CEO Riedemann.
Artículo de análisis • Jul 16

Here's Why We're Watching InflaRx's (NASDAQ:IFRX) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Jul 06

InflaRx stock rises 14% as vilobelimab gets FDA fast track status for skin disorder

The U.S. Food and Drug Administration (FDA) granted fast track designation to InflaRx's (NASDAQ:IFRX) vilobelimab to treat ulcerative pyoderma gangrenosum (PG). PG is a rare disorder which causes large, painful ulcers to develop on the skin, often on the legs. The company had had submitted a request for a fast track designation after positive data in a phase 2a trial in PG, Germany-based InflaRx said in a July 6 press release. Vilobelimab has already received orphan drug status for PG in the U.S. and EU. IFRX +14.08% to $1.62 premarket July 6
Seeking Alpha • Jun 29

InflaRx granted FDA Type B meeting to discuss submissions for COVID therapy

German biotech InflaRx N.V. (NASDAQ:IFRX) announced on Wednesday that the FDA agreed to a Type B meeting as the company seeks emergency use authorization for its COVID-19 therapy, vilobelimab  InflaRx (IFRX) has engaged the agency to discuss the future regulatory path for vilobelimab in COVID-19 after its multi-national PANAMO study for patients with the severe form of the disease generated favorable Phase 3 results early this year. The FDA has scheduled a Type B meeting for early Q3 to provide guidance on a potential emergency use authorization submission. Meanwhile, the discussions with the European Medicines Agency (EMA) are currently underway, targeting a regulatory submission for the same indication. Updating on the development of vilobelimab for the rare skin disorder pyoderma gangrenosum, InflaRx (IFRX) said that the company is now finalizing the design for a Phase III trial. That was after an end-of-phase II meeting, in which the FDA supported a randomized, controlled late-stage study and offered to review the study protocol. Read more on the topline data from the PANAMO study.
Artículo de análisis • Apr 01

Is InflaRx (NASDAQ:IFRX) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Dec 29

Our First Look At InflaRx

Today, we shine the spotlight on InflaRx, a small biotech concern based in Germany. The stock is deep in 'Busted IPO' territory even as the company has seen an increasing amount of news flow around it in recent months. A full investment analysis follows in the paragraphs below.

CEO

Niels Riedemann (52 yo)

19.3yrs
Permanencia

Prof. Dr. Niels C. Riedemann, M.D. is Chief Executive Officer of InflaRx N.V. since 2007 and serves as its Executive Director. He founded InflaRx N.V. in 2007 as InflaRx GmbH. He spent several years in bas...

Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Niels Riedemann
Co-Founder19.3yrssin datos0.73%
$ 2.8m
Renfeng Guo
Co-Founder19.3yrssin datos1.2%
$ 4.6m
Thomas Taapken
Chief Financial Officer5.6yrssin datos0.0024%
$ 9.1k
Derval O'Carroll
Senior VP and Global Head of Regulatory Affairs & Compliance3.1yrssin datos0%
$ 0
Camilla Chong
Chief Medical Officer2.8yrssin datos0%
$ 0
Jan Medina
Head of Investor Relations & VP2.3yrssin datossin datos
Christian Schmid
VP and Head of Legal Affairs & General Counselno datasin datossin datos
Maria Habel
VP, Head of Preclinical R&D and QC13.3yrssin datossin datos
Kofi Boaten
VP and Head of Supply Quality & Clinical Trial Suppliesno datasin datossin datos
Peter Hurt
Senior Director and Head of Drug Safety & Pharmacovigilianceno datasin datossin datos
Daniel Vetter
Senior Director & Head of IT3.8yrssin datossin datos
Igor Orshanskiy
Senior Director & Head of Business Development2.5yrssin datossin datos
3.8yrs
Permanencia media
57yo
Promedio de edad

Equipo directivo experimentado: El equipo directivo de IFRX se considera experimentado (3.8 años antigüedad media).

Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Niels Riedemann
Co-Founderno datasin datos0.73%
$ 2.8m
Renfeng Guo
Co-Founderno datasin datos1.2%
$ 4.6m
Nicolas Fulpius
Independent Chairman of the Board19.3yrssin datos0.33%
$ 1.3m
K. Reinhart
Member of Scientific Advisory Boardno datasin datossin datos
P. Ward
Member of Scientific Advisory Boardno datasin datossin datos
Richard Brudnick
Independent Non-Executive Director7yrssin datos0.034%
$ 130.5k
Hege Hellstrom
Non-Executive Director3.1yrssin datos0%
$ 0
Mark Kubler
Independent Non-Executive Director11.3yrssin datos0.65%
$ 2.5m
Anthony Gibney
Independent Non-Executive Director5yrssin datos0.0068%
$ 26.1k
7.0yrs
Permanencia media
54yo
Promedio de edad

Junta con experiencia: La junta directiva de IFRX se considera experimentada (7 años de antigüedad promedio).

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2026/05/26 23:25
Precio de las acciones al final del día2026/05/26 00:00
Beneficios2026/03/31
Ingresos anuales2025/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

InflaRx N.V. está cubierta por 16 analistas. 6 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
Madhu KumarBaird
Mayur SomaiyaBMO Capital Markets Equity Research
Madhu KumarB. Riley Securities, Inc.